India's Cadila Seeks To Cut The Pain Of GLP-1 Injectables As It Goes For Safety Studies Of Novel Oral Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Researchers at the sprawling Zydus Research Center located near the Western Indian city of Ahmedabad are upbeat about their latest finding - a novel orally administered GLP-1 agonist named ZYOG1- now ready to be tested on humans.
You may also be interested in...
Novo Nordisk Expects Strong Patient Benefits To Propel Victoza Sales In India But Will Pricing Get In The Way?
MUMBAI - Enthused by better-then-expected performance of its latest GLP-1 agonist Victoza (liraglutide) in the U.S., Novo Nordisk hopes that its new offering will find wide acceptance among Indian diabetologists and endocrinologists as it gears up for a nationwide launch. In addition to the U.S., Canada, India and E.U., Victoza has been introduced in a short span of time in 11 countries and will soon be available in Japan
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.